Amarin Corp Plc (AMRN)

[johngnatt]

When off-label use is 90% and on-label use is 10%, someone is doing something wrong, especially when the 90% is protected by a patent.

The party supplying the 90% which is beyond its authorized legal mandate?

The insurance approving the payment for the 90% off label, knowing that it can be a legal problem.

or PBM pushing for generics over branded for ALL indications?

The point I am making is when there is demand for off-label use for a patented indication, someone is fulfilling the demand in the supply chain and are there any "CONCRETE" legal precedent to object to this?

It looks like there are none.

Mfg- They asked for it, we gave it.

Doctor - They had it, so we gave it.